```
prompt_version: stage0-v15-20260331
model_info: claude-sonnet-4-6

[BIB-1] title: Asymmetric Synthesis of Quaternary Hydantoins via a Palladium-Catalyzed Aza-Heck Cyclization
[BIB-2] authors: Ellie A. Meck, Humair M. Omer, Montana J. Edwards, Temidayo D. Idowu, Mariah L. Murray, Katerina M. Korch, Donald A. Watson
[BIB-3] journal: Journal of the American Chemical Society
[BIB-4] year: 2025
[BIB-5] volume_pages: 147, 44692–44698
[BIB-6] doi: 10.1021/jacs.5c16022
[BIB-7] format: communication
[BIB-8a] target_paper_start: page 44692: [REDACTED: substantial verbatim quotation; see Tier 9]
[BIB-8b] target_paper_end: end of document

[S0-1] core_claim: An asymmetric, palladium-catalyzed aza-Heck cyclization of N-phenoxyamide substrates has been developed to prepare enantioenriched 5,5-disubstituted (quaternary) hydantoins. These products are obtained in high yields and enantioselectivities from substrates prepared in a single operation from α,β-unsaturated amides, and the method's drug-synthesis applicability [REDACTED: verbatim source text; see the source paper via its DOI]."

[S0-2] evidence_type: Reaction optimization table (Table 1, 5 entries varying Pd loading, solvent, and temperature; yield by ¹H NMR with internal standard, ee by SFC-MS); HTE ligand screen among 48 phosphoramidite/phosphite ligands (selected examples shown in Scheme 2); broad substrate scope (Scheme 3, ~24 products); aza-Wacker byproduct analysis as mechanistic evidence (Scheme 4); first asymmetric synthesis of (R)-mephenytoin (Scheme 5, 2 steps); ground state DFT calculations for conformational energy analysis of s-cis vs. s-trans starting material; gram-scale demonstration (5, 87% yield, 98% ee); absolute configuration assigned by deprotection to known (S)-stereoisomer.

[S0-3] prior_work_position: The paper frames quaternary enantioenriched hydantoin synthesis as "underdeveloped." Prior routes are dismissed as: (a) step-intensive and scope-limited (from α-amino acids or quaternary amino nitriles, refs 3–5); (b) high step count with highly specific C5 substituents (asymmetric Michael reactions, ref 6); (c) requiring both N-centers to be substituted and limited to Ph/terminal vinyl at C5 (Archambeau's multicomponent route, ref 9). Among asymmetric aza-Heck reactions specifically (refs 15), existing work is limited to pyrrolidine/piperidine or isoindolinone products, with no reported asymmetric synthesis of quaternary hydantoins. The Watson group's own prior aza-Heck work (refs 12–14) on racemic lactams, imidazolinones, and indolines is cited as precedent for the aza-Heck platform.

[S0-4] methodology: N-Phenoxyamide substrate 4 prepared in one step from α,β-unsaturated amide 3 via LiHMDS deprotonation, triphosgene treatment, and phenoxyamine HCl/Et₃N coupling. Aza-Heck cyclization: Pd(OAc)₂ (5 mol%), phosphoramidite ligand L1 [(S)-BINOL/(S)-1-aminoindane derived], BuCN solvent, Bu₃N base (5 equiv relative to electrophile), 40 °C, 0.5 mmol scale; isolated yields reported. Optimization run by high-throughput experimentation (HTE). Ee determined by SFC (crude product) or SFC-MS (HTE). Absolute configuration established by CAN-mediated PMB deprotection to give known (S)-hydantoin 25. DFT ground state calculations for conformational energy analysis. (R)-Mephenytoin synthesis uses ligand L9 [(S)-spinol/(S)-1-aminoindane derived], followed by Pd/C hydrogenation.

[S0-5] conclusion_reach: The reaction provides a wide range of quaternary hydantoins (24 examples in Scheme 3) in high yields (typically >80%) and excellent ee (typically >90:10 er), with broad functional group tolerance (heterocycles, esters, chlorides, fluorides). Limitations acknowledged: bromide-substituted substrate gives reduced yield with competing Ar–Br activation byproducts; tetrasubstituted alkenes require elevated temperature (75 °C) with somewhat lower ee; larger N-alkyl chains (Et, Cy) give lower yield and ee; N-Ph and unsubstituted N-H substrates do not cyclize; substrates with alkyl groups on both nitrogens fail (footnote 23). A 5% racemic aza-Wacker byproduct (26) is noted for the model substrate. The (R)-mephenytoin synthesis proceeds in 43% yield/70% ee with standard ligand (L1), improving to 69% yield/91% ee with optimized ligand L9.

[S0-6] next_question_stated: [REDACTED: substantial verbatim quotation; see Tier 9]

[S0-7] note_added_in_proof: none.

inference_time_sec: not available — inject externally
```

---

> **Tier 8 redaction notice**: This file is a redacted copy of the corresponding Tier 3 / Tier 9 output. Verbatim source-paper quotations have been replaced by `[REDACTED: see source paper §<loc>; full text retained in Tier 9 reviewer-only deposit]` markers, preserving location references and our own analytical content. Bibliographic fields (title, authors, journal, year, DOI), analytical labels (`evidence_chain:` with B-/U-/A-/C- internal IDs), short technical terms, and our own analytical text are not redacted. The redaction was applied by `scripts/redact_for_tier8.py` and, for this version, by `scripts/build_paperA_R1_public.py` with `scripts/redact_source_ngram_runs.py` (scripts of the project repository; they are not deposited).
